Franklin-based medical device and pharmaceutical company Echo Therapeutics said a key component of the company’s glucose monitoring system has been granted a patent.
The patent covers the composition and methods for the preparation of a polyethylene glycol-based gel that enables Echo’s system to sense glucose levels through the skin.
The system is called the Symphony Transdermal Continuous Glucose Monitoring System and is in late-stage development for the diabetes care market. The system is for home and hospital use, the company said.
